Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer.
作者信息
Rasmussen Maja Lynge, Liposits Gabor, Yogendram Subethini, Jensen Anders Bonde, Linnet Søren, Langkjer Sven Tyge
机构信息
Department of Oncology, Aarhus University Hospital , Aarhus , Denmark.
出版信息
Acta Oncol. 2014 Sep;53(9):1275-7. doi: 10.3109/0284186X.2014.918277. Epub 2014 May 20.
PMID:24844919
Abstract
摘要
相似文献
1
Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer.
Acta Oncol. 2014 Sep;53(9):1275-7. doi: 10.3109/0284186X.2014.918277. Epub 2014 May 20.
2
[A long-term response to eribulin].
Bull Cancer. 2018 Jul-Aug;105(7-8):636-638. doi: 10.1016/j.bulcan.2018.05.002. Epub 2018 Jun 14.
3
Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Future Oncol. 2015;11(15 Suppl):31-6. doi: 10.2217/fon.15.151.
4
Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
Breast. 2016 Dec;30:73-79. doi: 10.1016/j.breast.2016.08.015. Epub 2016 Sep 14.
5
Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.
Future Oncol. 2015;11(15 Suppl):23-6. doi: 10.2217/fon.15.149.
6
Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies.
Future Oncol. 2018 Mar;14(7s):29-36. doi: 10.2217/fon-2017-0358.
7
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
Ann Oncol. 2012 Jun;23(6):1441-8. doi: 10.1093/annonc/mdr444. Epub 2011 Oct 11.
8
Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.
9
Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Future Oncol. 2017 Apr;13(11s):5-10. doi: 10.2217/fon-2017-0017.
10
Practical experiences with eribulin in patients with metastatic breast cancer.
Anticancer Drugs. 2016 Feb;27(2):112-7. doi: 10.1097/CAD.0000000000000288.
引用本文的文献
1
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
BMC Cancer. 2015 Oct 8;15:659. doi: 10.1186/s12885-015-1673-3.
Zotero 插件